Hot Seat: Which Agent, and When? Integrating Next-Generation Endocrine Strategies Into HR+/HER2– Breast Cancer Management

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description

In this podcast, experts Ruta D. Rao, MD; Kamel Abou Hussein, MD; Jame Abraham, MD, FACP; and Paolo Tarantino, MD, PhD, discuss the data supporting the approvals of next-generation endocrine therapies for ESR1-mutated hormone receptor (HR)–positive, HER2-negative metastatic breast cancer, and how they think through these data when individualizing treatment recommendations for these patients.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Select among available next-generation endocrine monotherapies and combination strategies for patients with ESR1-mutant, HR+/HER2– advanced breast cancer after CDK4/6 inhibitor progression based on clinical trial data, mutation profile, and patient-specific factors

Acknowledgment of Educational Grant Support

This activity is supported by educational grants from Stemline Therapeutics, Inc and Rigel Pharmaceuticals, Inc.

Chair:

Ruta D. Rao, MD

Professor of Medicine
Director, Coleman Foundation Comprehensive Breast Cancer Clinic
Medical Director, RUSH University Cancer Center
Chicago, IL

Disclosures: Consultant/Advisor: Daiichi Sankyo, Genentech, Lilly, Pfizer, TerSera.

Faculty:

Kamel Abou Hussein, MD

Assistant Professor of Medicine
Cooper Medical School of Rowan University
Co-Director, Janet Knowles Breast Cancer Center
Cooper University Health Care
Camden, NJ

Disclosures: Advisor, Consultant, Fee-for-Service Recipient: AstraZeneca; Speakers Bureau: Lilly, Menarini-Stemline.

Jame Abraham, MD, FACP

Enterprise Chair, Department of Hematology and Medical Oncology
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Cleveland, OH

Disclosures: Advisory Board: OpenEvidence, ThinkBio.AI.

Paolo Tarantino, MD, PhD

Clinical Fellow Breast Oncology Center
Dana-Farber Cancer Institute
Harvard Medical School
Boston, MA

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all conflict of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

The staff of Physicians’ Education Resource^®, LLC, have no relevant financial relationships with ineligible companies.

This podcast, including the narration, was developed by PER^® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.

To learn more about this topic, including information on next-generation endocrine therapies in the frontline metastatic setting for HR+/HER2– advanced breast cancer, and in early-stage HR+/HER2– breast cancer, go to https://www.gotoper.com/courses/hot-seat-which-agent-and-when-integrating-next-generation-endocrine-strategies-into-hrher2-breast-cancer-management-rjgd.

Release Date

July 24, 2026

Expiration Date

July 24, 2027

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.